evipedia.ai
← Back

Nicotinamide Riboside for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: NR, Niagen, Tru Niagen, Nicotinamide Riboside Chloride, N-ribosylnicotinamide

Motivation

Nicotinamide riboside (a form of vitamin B3) is sold as a supplement meant to restore a molecule that cells depend on to release energy from food and repair damaged DNA. Levels of that molecule have been reported to fall in ageing tissue, and the idea that topping it up might slow biological ageing has made it one of the most heavily marketed longevity compounds available.

The compound was identified as a vitamin precursor in the mid-2000s, and human testing began about a decade later. Since then dozens of trials have tested it in healthy adults and in people with heart, lung and brain conditions. Nearly every trial has found that it raises the target molecule in blood; whether anything measurable improves as a result is disputed. Sales have meanwhile grown into a substantial industry, and much of the research has been paid for by the companies that sell it.

This review examines what nicotinamide riboside does inside cells, which outcomes have been measured in people and how strong that evidence is, what harms have been reported or proposed, how it is dosed and sourced, and what the trials now under way are likely to settle.

Benefits - Risks - Protocol - Conclusion

High-level overviews of nicotinamide riboside and the NAD+ (nicotinamide adenine dinucleotide, the molecule cells use to release energy from food, repair DNA and regulate genes) hypothesis from prioritized longevity-focused sources, chosen to span both the supportive and the sceptical readings.

No Chris Kresser item qualified for the list above: a direct search of chriskresser.com returns three aging-related items — the Revolution Health Radio episodes with David Sinclair and with Mark Hyman, and the article “Nutrition and Aging: What to Eat for a Long and Healthy Life” — and all three name nicotinamide riboside only in a passing line alongside nicotinamide mononucleotide, rather than covering the compound in substantial depth.

Grokipedia

Nicotinamide riboside

Covers structure, stability, the two-step conversion route to NAD+, clinical evidence, commercialisation history and regulatory status, with an unusually detailed section on degradation and alternative supplementation approaches.

Examine

Nicotinamide Riboside

Examine’s dedicated supplement page, written by Kamal Patel and updated in August 2025, files the compound under Healthy Aging & Longevity and links a continuously updated feed of the underlying human studies.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

The only independent laboratory testing of this category, reporting how much nicotinamide riboside products actually contain, which are counterfeit, and where the advertising claims have been challenged. Full results require membership.

Systematic Reviews

Systematic reviews and meta-analyses covering both the claimed benefits of NAD+ precursors and their safety profile.

Mechanism of Action

Nicotinamide riboside (NR) is a ribose-linked form of nicotinamide, one of several chemical shapes vitamin B3 takes. Cells convert it in two steps: nicotinamide riboside kinases 1 and 2 (NRK1/NRK2, enzymes that attach a phosphate group) make nicotinamide mononucleotide (NMN), which adenylyltransferases finish into NAD+ — the cofactor cells use to release energy from food, repair DNA and regulate genes.

NAD+ is continuously consumed rather than merely recycled. Sirtuins (NAD+-dependent enzymes that regulate metabolism and gene silencing), poly(ADP-ribose) polymerases (PARPs, DNA-repair enzymes) and CD38 (an NAD+-degrading enzyme on immune cells that becomes more active with age) all break it down, so supply is thought to limit their activity.

NR has no receptor target and no cytochrome P450 (the liver’s main drug-metabolising enzyme family) involvement. Plasma NR peaks within about an hour with a half-life near two to three hours; whole-blood NAD+ rises over roughly two weeks, then plateaus. Clearance is mainly as methylnicotinamide via nicotinamide N-methyltransferase (NNMT, which tags nicotinamide with a methyl group for excretion), and distribution favours liver, blood and muscle over brain.

A competing account holds that little oral NR reaches tissues intact: it is largely degraded to nicotinamide in gut and liver, and a 2026 human comparison found gut bacteria convert NR and NMN to nicotinic acid, which raises circulating NAD+ through the Preiss-Handler route (the pathway building NAD+ from nicotinic acid). On that reading, higher blood NAD+ need not mean higher brain, heart or muscle NAD+.

Historical Context & Evolution

Nicotinamide riboside was first described in the 1940s as a growth factor for Haemophilus influenzae, a bacterium that cannot make its own NAD+. It sat largely unstudied for six decades. In 2004 Charles Brenner’s laboratory identified the nicotinamide riboside kinase enzymes and showed that yeast and human cells use NR as a distinct vitamin B3 route to NAD+ — the first new vitamin precursor pathway described in decades.

Interest in raising NAD+ pre-dates NR itself. Nicotinic acid (niacin) had been given in gram doses since the 1950s to lower cholesterol, and reports through the 2000s that tissue NAD+ falls with age, together with rodent work linking NAD+ to sirtuins and to calorie restriction, made repletion an attractive idea. NR was commercialised from 2013 as Niagen, a crystalline chloride salt, and became the first NAD+ precursor with formal United States food-safety notifications and, later, European novel-food authorisation.

The original rodent findings — improved mitochondrial function, muscle stem-cell rejuvenation, and about five percent longer median lifespan when started in old mice — have not been retracted, and the human trials that followed have generally confirmed the biochemical effect while failing to reproduce the functional gains. Whether that gap reflects dose, duration, species differences or an overstated premise is unsettled; a 2026 human study questioning whether blood NAD+ falls with age at all has reopened the mechanistic question rather than closing it.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the positive human results are single randomized trials of walking distance or motor scores plus inflammatory-marker and metabolite changes, with no clinical endpoint or validated clinical surrogate reproduced in more than one trial.

Medium 🟩 🟩

Walking Distance in Peripheral Artery Disease

Peripheral artery disease (narrowed leg arteries that cause pain on walking) limits walking partly through poor muscle mitochondrial function. In the 90-person NICE randomized controlled trial (RCT — participants assigned to treatment or placebo by chance), six months of NR lengthened six-minute walk distance versus placebo, with a larger gain among those taking at least 75% of capsules. This is one trial reported with a one-sided 90% confidence interval (CI — the range likely containing the true effect); a confirmatory phase 3 trial has not begun.

Magnitude: +17.6 metres versus placebo at six months (one-sided 90% CI +1.8 to +∞); +31.0 metres among participants taking at least 75% of study capsules.

Motor Symptom Scores in Early Parkinson’s Disease

Parkinson’s disease involves failing mitochondrial energy production in dopamine neurons. In a 30-person phase 1 trial, 30 days of NR raised brain NAD+ in about half of recipients; those responders showed altered brain glucose metabolism and mild improvement on the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS, a standard motor and daily-function score). A later high-dose safety trial also recorded improvement, though confounded by levodopa timing. The definitive 410-person phase 3 trial completed in 2025 and remains unpublished.

Magnitude: Direction only — mild MDS-UPDRS improvement confined to participants whose brain NAD+ actually rose, in a phase 1 trial not powered for efficacy; the literature reports no outcome figure for motor progression.

Low 🟩

Systolic Blood Pressure and Arterial Stiffness

In a 24-person crossover trial, six weeks of NR lowered systolic blood pressure modestly overall — not significant after correcting for multiple comparisons — and by more in participants starting above 120 mmHg. That subgroup analysis was exploratory and post hoc; aortic stiffness moved in the same direction without significance.

Magnitude: Mean systolic pressure fell 3.9 mmHg overall and was 9 mmHg lower after NR than placebo in the 13 participants whose baseline reading sat in the elevated or stage 1 hypertension range.

Body Composition and Resting Energy Expenditure ⚠️ Conflicted

Six weeks of 1000 mg daily raised fat-free mass and sleeping metabolic rate in 13 overweight adults, and increased muscle acetylcarnitine (a fat-burning intermediate). The same trial found no change in insulin sensitivity or liver fat. A larger obesity trial found no body-composition effect. Net reading: an isolated, unreplicated finding.

Magnitude: Fat-free mass rose 1.34 percentage points versus placebo (62.65% against 61.32%); muscle acetylcarnitine rose from about 3,025 to 4,558 pmol per mg dry weight.

Speculative 🟨

Whole-Blood and Tissue NAD+ Availability

Oral NR raises NAD+ dose-dependently in blood — 22%, 51% and 142% at 100, 300 and 1000 mg daily — and reaches skeletal muscle and white blood cells. Target engagement only; NAD+ is an unvalidated biomarker.

Circulating and Airway Inflammatory Markers

NR lowered interleukin-6 and tumour necrosis factor alpha (signalling proteins that drive inflammation) in aged men and cut sputum interleukin-8 52.6% in obstructive lung disease. No trial has shown fewer infections, flares or events.

Neuronal Markers of Neurodegenerative Pathology

In 22 older adults NR raised NAD+ and lowered amyloid-beta 42 inside neuron-derived blood vesicles. Cognition did not change here or in a separate trial in mild cognitive impairment (memory loss short of dementia).

Reduced Epigenetic Age and Senescence Markers

Exploratory analyses in a small trial showed modest gains in DNA methylation and lower estimated epigenetic age. Epigenetic clocks are unvalidated ageing biomarkers, and the analysis was neither pre-specified nor corrected for multiple testing.

Lifespan Extension

Rodent work reports roughly 5% longer median lifespan when NR begins in old mice, alongside muscle stem-cell rejuvenation. No human lifespan or mortality data exist; the basis is animal work only.

Benefit-Modifying Factors

  • Baseline NAD+ status: The rise in blood NAD+ is inversely related to the starting level, so the least depleted respond least. A 2026 multi-cohort analysis found blood NAD+ does not track age, undermining the assumption that older users are more depleted.

  • NRK1 expression: Nicotinamide riboside kinase 1 performs the rate-limiting first conversion step, and its expression varies widely between tissues and individuals. Low expression means an oral dose is degraded to nicotinamide before any cell can use it as NR.

  • Methylation genetics: Disposing of surplus nicotinamide consumes methyl groups. Carriers of the MTHFR C677T variant (which slows the enzyme that activates folate) and those with low folate or vitamin B12 have less methyl-donor reserve to spare.

  • Gut microbiome composition: Because much of the NAD+ rise appears to depend on bacterial conversion of NR to nicotinic acid, antibiotic use or an atypical microbiome may blunt the response. This is inferred from one 2026 human trial and has not been tested directly.

  • Sex: Two of the most-cited mechanistic trials enrolled men only, and no trial has been powered to compare responses between sexes. Whether the muscle and metabolic findings extend to women is untested rather than negative.

  • Age: Trials have enrolled adults from 40 to 83. The only functional benefit reproduced in older participants was in disease (peripheral artery disease); in unselected adults over 60, pooled trials found no gain in strength, gait speed or muscle mass.

  • Pre-existing disease burden: Every positive functional result has come from a diseased population — narrowed leg arteries, Parkinson’s disease, obstructive lung disease. Healthy middle-aged adults show biochemical change without measurable functional change.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Gastrointestinal, Flushing and Skin Adverse Events

Across randomized trials at 300–3000 mg daily, participants have reported nausea, stomach discomfort, flushing (transient warmth and reddening of the skin), itching, rash, leg cramps and easy bruising. Severity has been uniformly mild, no serious adverse event has been attributed to NR, and rates have not separated from placebo in the trials that counted them formally.

Magnitude: In a 30-person crossover trial, 14 mild treatment-emergent events occurred across both arms — 5 on NR and 9 on placebo — and the only two dropouts for side effects both happened during the placebo phase.

Medium 🟥 🟥

Decline in Timed Physical Performance in Mild Cognitive Impairment

A 2025 systematic review’s narrative synthesis found that in mild cognitive impairment, NR groups scored lower on the Short Physical Performance Battery (a timed balance, walking and chair-rise test) and were slower on the five-time chair-stand test than placebo. The underlying trials were small and not designed for these endpoints, and one reported that walking speed improved in the placebo arm through practice, so the signal may not be causal.

Magnitude: Direction only — the review reports lower Short Physical Performance Battery scores and slower chair-stand times on NR in this population without pooling them into an effect size, and the literature gives no outcome figure.

Low 🟥

Rising Plasma Homocysteine at High Doses ⚠️ Conflicted

Disposing of surplus nicotinamide consumes methyl groups, which can raise homocysteine (an amino acid linked to vascular risk). A 3000 mg trial saw homocysteine rise without depleting methyl donors; an eight-week trial up to 1000 mg saw none. Net reading: a dose-dependent effect above roughly 1000 mg daily.

Magnitude: Serum homocysteine rose 1.66 µmol/L from baseline over four weeks at 3000 mg daily — the rise present by day 3 and stable thereafter — while methyl-donor status stayed intact; no change occurred at 100–1000 mg daily over eight weeks.

Niacin-Equivalent Intake Above the Tolerable Upper Limit

NR is metabolised to nicotinamide, so it counts toward vitamin B3 intake. Typical supplemental doses deliver several times the United States upper intake level, though European regulators set a far higher separate ceiling for nicotinamide, and the two authorities disagree on what the relevant limit is.

Magnitude: A 300 mg dose of nicotinamide riboside chloride supplies roughly 126 mg of nicotinamide equivalents — about 3.6 times the 35 mg United States upper intake level for niacin, but under one-seventh of the 900 mg European upper level for nicotinamide.

Reduced Cerebral Blood Flow in Default-Mode Regions ⚠️ Conflicted

In a 20-person trial in mild cognitive impairment, ten weeks of NR reduced blood flow through the default mode network (brain regions most active at rest), though not surviving correction for multiple comparisons. A larger 2026 trial found no change in total flow. Net reading: the reduction is unreplicated.

Magnitude: Mean flow difference 0.92 in the default mode network (95% CI 0.23 to 1.62, P = 0.013 — P is the probability a difference this large would arise by chance alone) and 1.66 in the left inferior parietal lobe (95% CI 0.5 to 2.82, P = 0.009); neither survives correction for multiple comparisons.

Rising Plasma Glucose

NAD+ precursors as a class raised plasma glucose in a meta-analysis of forty studies, though the effect was driven mainly by nicotinic acid rather than nicotinamide riboside. Trials of nicotinamide riboside itself have found no glucose change, so the signal is indirect.

Magnitude: Pooled across the precursor class, plasma glucose rose modestly (effect size 0.27, 95% CI 0.12 to 0.42); no nicotinamide riboside trial has reported a rise.

Speculative 🟨

Promotion of Existing or Occult Cancer

Tumour cells depend heavily on NAD+ for sugar breakdown. NR supplementation increased tumour burden and brain spread in a mouse triple-negative breast cancer model; an earlier four-mice-per-group pilot showed similar growth. No human data exist.

Interference with Treatments That Rely on NAD+ Depletion

Some cancer therapies work by starving cells of NAD+ or by exhausting it during DNA repair. Restoring supply could in principle blunt them. The basis is mechanistic reasoning; no clinical report has tested it.

Risk-Modifying Factors

  • Undiagnosed or previously treated malignancy: The tumour-promotion signal, if real, would act on cancer that already exists rather than initiating it. A personal history of cancer, or an age and family history that make occult disease likelier, shifts the balance.

  • Cumulative vitamin B3 intake: Multivitamins, fortified foods, energy drinks and separate niacin or nicotinamide supplements stack with NR. Someone already at the upper intake level from other sources reaches a much higher total than the label dose implies.

  • Methylation reserve: Low folate, low vitamin B12, high alcohol intake or the MTHFR C677T variant reduce the methyl groups available to clear surplus nicotinamide, making a homocysteine rise likelier at doses above 1000 mg daily.

  • Cognitive status: The only human signal of functional harm — slower timed performance and reduced resting brain blood flow — appeared specifically in people with mild cognitive impairment, not in cognitively intact adults.

  • Sex: No sex-specific adverse-event pattern has been reported, but several trials enrolled men only, so a female-specific signal would not yet have been detected. This is an evidence gap rather than reassurance.

  • Age and organ function: Clearance is hepatic and renal. Trials excluded severe liver or kidney impairment, so the tolerability record does not extend to older adults with Child-Pugh Class B or C liver disease or advanced kidney disease.

Key Interactions & Contraindications

  • Cytotoxic chemotherapy and radiotherapy — caution, oncologist decision: Both work partly by causing DNA damage that consumes NAD+. Replenishing it could theoretically reduce tumour kill. Protocols suspend nicotinamide riboside for the duration of treatment unless the treating oncologist directs otherwise.

  • PARP inhibitors (olaparib, niraparib, talazoparib) — caution, theoretical antagonism: These block a DNA-repair enzyme that consumes NAD+; raising NAD+ supply may work against the intended effect. Consequence would be reduced anticancer efficacy. The supplement is stopped for the duration of therapy.

  • Investigational NAMPT inhibitors (daporinad, KPT-9274) — absolute contraindication: These deliberately starve tumours of NAD+ by blocking the enzyme that recycles nicotinamide. Nicotinamide riboside bypasses that block entirely, nullifying the drug. The combination is contraindicated without exception.

  • Antihypertensive medication (amlodipine, lisinopril, losartan) — monitor: The one controlled signal in humans was a modest fall in systolic pressure. Additive lowering could cause light-headedness on standing. Weekly home readings for the first month are the usual precaution.

  • Levodopa/carbidopa — no interaction identified, monitor: Two Parkinson’s trials co-administered nicotinamide riboside with standard dopaminergic therapy without pharmacokinetic interference or added adverse events. Dose timing is recorded, since it can confound symptom scoring.

  • Other vitamin B3 supplements (niacin, nicotinamide, nicotinamide mononucleotide, NADH — the reduced form of NAD+) — additive, cap total intake: All converge on the same nicotinamide pool. Stacking risks exceeding upper intake levels and driving methyl-group depletion. A single precursor is the usual practice.

  • Over-the-counter multivitamins, fortified cereals and energy drinks — additive: Routinely supply 20–100 mg of niacin equivalents before any supplement is added. Consequence is silent overshoot of the upper intake level. What matters is total daily vitamin B3 from all sources, not the NR dose alone.

  • Methyl-donor supplements (trimethylglycine, methylfolate, vitamin B12) — mitigating, beneficial: These replace the methyl groups consumed clearing surplus nicotinamide, blunting any homocysteine rise. Commonly added at 500–1000 mg trimethylglycine daily when nicotinamide riboside exceeds 1000 mg.

  • Sirtuin-activating supplements (pterostilbene, resveratrol) — potentiating, caution: Co-formulated in several commercial products. They increase demand on the NAD+ pool the supplement is raising. The one repeat-dose trial of the combination raised cholesterol rather than liver enzymes, so a lipid panel is the relevant check.

  • CD38-inhibiting flavonoids (apigenin, quercetin) — potentiating: These slow NAD+ degradation, so combining them with a precursor raises levels more than either alone. No safety signal is documented, but the effective NAD+ exposure exceeds what the labelled dose suggests.

  • Alcohol — antagonistic: Ethanol metabolism consumes the oxidised form of NAD+ and shifts the cellular ratio toward the reduced form, working directly against the intended effect. Heavy intake also depletes the methyl donors needed to clear nicotinamide.

  • Prolonged fasting and endurance exercise — overlapping mechanism: Both raise NAD+ through the salvage pathway (the route recycling nicotinamide back into NAD+) the supplement feeds. No harm is documented, but any benefit may be redundant in someone already fasting or training regularly.

Populations who should avoid Nicotinamide Riboside:

  • Anyone with active malignancy, measurable residual disease, or a cancer treated within the past 5 years
  • Anyone receiving a PARP inhibitor, an investigational NAMPT inhibitor, or cytotoxic chemotherapy
  • Pregnant and lactating women — excluded from every trial and from the European novel-food authorisation
  • Children and adolescents under 18 years
  • Severe hepatic impairment (Child-Pugh Class B or C) or advanced kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m²)
  • Known hypersensitivity to niacin or nicotinamide

Risk Mitigation Strategies

  • Starting dose of 250–300 mg once daily: The dose at which whole-blood NAD+ already rises about 50% and at which no adverse-event excess has been recorded. Avoids the homocysteine and upper-intake-limit concerns that attach to gram doses.

  • Total vitamin B3 tracked from all sources: The niacin equivalents in multivitamins, fortified foods and energy drinks are added to the supplement dose. Prevents silent accumulation past the 35 mg United States upper intake level for niacin.

  • Trimethylglycine 500–1000 mg daily above 1000 mg: Replaces methyl groups consumed clearing surplus nicotinamide, mitigating the homocysteine rise recorded at 3000 mg daily. Unnecessary at 300 mg, where no methylation change has been observed.

  • Cancer screening before starting where risk is elevated: Age-appropriate screening — colonoscopy, mammography, prostate-specific antigen — completed before the first dose. Addresses the tumour-promotion concern, which applies to existing disease rather than new cancers.

  • Homocysteine and liver enzymes rechecked at 8–12 weeks: Catches the two laboratory changes plausibly linked to cumulative nicotinamide load before they persist. A repeat follows 4 weeks after any dose increase above 1000 mg daily.

  • Third-party-verified product from an authorised seller: Label claim and actual nicotinamide riboside content diverge widely across the market, and counterfeits circulate. Mitigates both wasted expenditure and unknown contaminants.

  • A 2-week pause before any planned oncology treatment: Clears the raised NAD+ pool before therapies whose mechanism depends on NAD+ depletion or DNA damage, addressing the theoretical loss of anticancer efficacy.

  • Dosing with the morning meal: Reduces the nausea reported in trials and aligns dosing with the daily NAD+ peak, addressing both gastrointestinal tolerability and any sleep disturbance from evening dosing.

Therapeutic Protocol

  • Standard dose: 250–300 mg of nicotinamide riboside chloride once daily, the dose used in the marketed Niagen and Tru Niagen products and the one at which whole-blood NAD+ rises about 50% within two weeks.

  • Research dose range: Human trials have used 300–2000 mg daily for 6–24 weeks, with a Norwegian safety trial reaching 3000 mg daily for 4 weeks. Above 1000 mg no additional functional benefit has been demonstrated.

  • Best time of day: Morning, with food. NAD+ synthesis follows a daily rhythm that peaks early, trial dosing was predominantly morning, and food reduces the nausea reported at gram doses.

  • Half-life: Nicotinamide riboside itself peaks in plasma within about an hour and clears with a half-life near two to three hours, but the whole-blood NAD+ it produces rises over two weeks and then holds steady.

  • Single or split dosing: A single morning dose sustains the NAD+ elevation because the effect follows the plateau, not the peak. Trials using 1000 mg or more split the dose twice daily, mainly to limit gastrointestinal upset.

  • Competing approach — the nicotinamide riboside position: Charles Brenner, who identified the pathway and served as ChromaDex’s chief scientific officer, argues nicotinamide riboside is the best-characterised precursor with the strongest safety documentation.

  • Competing approach — the nicotinamide mononucleotide position: David Sinclair’s Harvard group favours nicotinamide mononucleotide at 250–1000 mg daily, arguing it sits one step closer to NAD+. Head-to-head human data show the two raise blood NAD+ comparably.

  • Competing approach — nicotinic acid: Eija Pirinen’s group used 750–1000 mg daily of nicotinic acid in mitochondrial myopathy (inherited muscle weakness from failing cell power plants), raising muscle NAD+ at a fraction of the cost. Trade-off: pronounced skin flushing.

  • Competing approach — decline to supplement: Peter Attia and Matt Kaeberlein hold that no precursor has shown a lifespan or healthspan effect in humans and that the expenditure is not yet justified by evidence.

  • Competing approach — intravenous NAD+ infusion: Longevity clinics offer 250–1000 mg infusions over several hours. The 2026 systematic review found no outcome trial of intravenous NAD+ for longevity or wellness indications at all.

  • Genetic considerations: No pharmacogenetic test guides dosing. MTHFR C677T carriers and those with low folate or vitamin B12 have less methyl-donor reserve, which argues for staying at 300 mg rather than escalating.

  • Sex-based considerations: Several key mechanistic trials enrolled men only and none was powered to compare sexes, so no sex-specific dose has been established. Current practice applies the same dose to both.

  • Age-related considerations: Adults up to 83 have been dosed without an age-related tolerability signal. In those over 60 with mild cognitive impairment, timed physical performance moved the wrong way, which argues for caution rather than a higher dose.

  • Baseline biomarker considerations: The NAD+ response is largest in those starting lowest, and the blood-pressure signal appeared only in participants above 120 mmHg systolic. Both argue for measuring before starting rather than assuming benefit.

  • Pre-existing conditions: Every reproducible functional result came from a diseased population. Peripheral artery disease, Parkinson’s disease and obstructive lung disease are the contexts with supporting trial data; healthy adults have shown biochemical change only.

Discontinuation & Cycling

  • Not a lifelong commitment by design: Nicotinamide riboside is a vitamin form, not a chronic medication, and no trial has run beyond 24 weeks except an open-label extension. Long-term continuous use is untested rather than established as safe.

  • No withdrawal effects: No trial has reported rebound symptoms, and the safety extension studies recorded none on cessation. Blood NAD+ simply returns toward baseline as the salvage pathway resumes its usual rate.

  • No taper required: Because there is no receptor adaptation and no dependence mechanism, stopping abruptly is as safe as tapering. The absence of a taper protocol reflects the absence of any need for one.

  • Washout kinetics: Whole-blood NAD+ falls back toward baseline over roughly one to two weeks after the last dose, mirroring the two weeks it takes to rise. This sets the pause interval before oncology treatment.

  • Cycling: No trial has compared continuous with intermittent dosing, and no tolerance or receptor downregulation has been demonstrated that cycling would address. Schedules such as five days on and two off are practitioner convention without supporting evidence.

Sourcing and Quality

  • The form the trials used: Almost every published human trial used nicotinamide riboside chloride marketed as Niagen. Other salts and unbranded material have no clinical documentation and no food-safety notification behind them.

  • Actual nicotinamide riboside content: Labels often state the salt weight, not the free-base weight, and hydrogen malate contains substantially less nicotinamide riboside per milligram than the chloride. A 300 mg chloride capsule delivers about 263 mg of free base.

  • Third-party verification: The markers are a batch certificate of analysis or a mark from NSF International or the United States Pharmacopeia, both independent testing organisations. Without one, the label figure is unverified and shortfalls in delivered dose are common.

  • Authorised sellers: Counterfeit Tru Niagen has been identified on major marketplaces, and a trade-press report on the manufacturer’s market survey says 29 of 39 products tested contained far less nicotinamide riboside than claimed. The brand’s own store or an authorised retailer avoids that exposure.

  • Cool, dry, sealed storage: Nicotinamide riboside chloride is hygroscopic and degrades to plain nicotinamide with heat and humidity, so a product stored in a bathroom cabinet may deliver ordinary vitamin B3 at a premium price.

  • Products with published testing behind them: Tru Niagen (ChromaDex), Thorne NiaCel, Life Extension NAD+ Cell Regenerator and Elysium Basis all use the branded chloride. Note that ChromaDex funded much of the supporting research and Elysium funded its own trials.

Practical Considerations

  • Time to effect: Blood NAD+ rises within two weeks and then plateaus, but no functional outcome has appeared that quickly. The walking-distance result required six months, and the lung-inflammation result six weeks.

  • Common pitfall — treating blood NAD+ as proof of benefit: Rising blood levels confirm absorption, nothing more. A 2026 multi-cohort analysis found blood NAD+ does not vary with age or lifestyle, weakening its use as an ageing marker.

  • Common pitfall — expecting an immediate energy effect: Marketing emphasises energy, but the controlled evidence does not support it. A controlled trial of whole-body and muscle responses to endurance exercise found no effect.

  • Common pitfall — escalating the dose without cause: Above 1000 mg daily the evidence adds cost and a homocysteine signal without adding demonstrated benefit. Dose escalation is the most common self-directed change and the least supported.

  • Regulatory status: A lawful dietary ingredient in the United States under two new dietary ingredient notifications and generally-recognized-as-safe status, and authorised as a novel food in the European Union. Sold over the counter; no prescription applies.

  • Cost and accessibility: Roughly USD 30–50 monthly for 300 mg daily, widely available online; plain nicotinamide costs a small fraction. No insurer or health system reimburses any form, so structural bias here comes from manufacturer funding rather than from institutional payers.

Interaction with Foundational Habits

  • Sleep: Direction uncertain, no controlled evidence. NAD+ synthesis is governed by the same clock machinery that sets the sleep-wake cycle, which is the rationale for morning dosing; evening dosing is anecdotally associated with alertness and vivid dreams. A dedicated polysomnography trial (NCT07284225) is registered but not yet under way, leaving the question open.

  • Nutrition: Directly overlapping. Nicotinamide riboside is a vitamin B3 form and adds to niacin equivalents from meat, fish, fortified grains and dietary tryptophan. Clearing the surplus consumes methyl groups, so folate, vitamin B12, choline and betaine intake matter; alcohol works against the effect by shifting the cellular NAD+ ratio.

  • Exercise: Possibly blunting, not potentiating. Training raises NAD+ through the same salvage pathway, and in aged men nicotinamide riboside downregulated muscle energy-metabolism and mitochondrial gene programmes without improving mitochondrial function. A separate trial found no change in the response to a single endurance session. Nothing supports use as a workout aid.

  • Stress management: Indirect and speculative. NAD+-dependent sirtuins sit downstream of the same metabolic-stress signalling that fasting and exercise engage, but no trial has measured cortisol, heart-rate variability or any validated stress outcome. The plausible mechanism has never been tested in people.

Monitoring Protocol & Defining Success

Baseline testing before the first dose gives the only reference point that matters later, because none of these markers has a target specific to nicotinamide riboside. The baseline set is a fasting panel covering homocysteine, high-sensitivity C-reactive protein, liver enzymes, fasting glucose and glycated haemoglobin, together with a week of home blood-pressure readings; for men over 45 a prostate-specific antigen value is added. Whole-blood NAD+ testing is optional and serves only to confirm absorption.

The panel is repeated at 8–12 weeks, once blood NAD+ has plateaued and any methyl-group effect would have appeared, then at 6 months and every 6–12 months thereafter. Blood pressure is re-checked monthly for the first three months in anyone starting above 120 mmHg systolic. Escalation above 1000 mg daily calls for a homocysteine and liver-enzyme retest 4 weeks after the increase.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Whole-blood nicotinamide adenine dinucleotide No established target; track the change from the individual’s own baseline, where a 40–150% rise is typical Confirms absorption and conversion Specialist mail-in assay; values differ widely between laboratories, so compare only within one provider. A 2026 multi-cohort study found it does not track age, so treat it as a compliance check rather than an ageing marker
Homocysteine 5–8 µmol/L Detects methyl-group drain from clearing surplus nicotinamide Conventional laboratories flag only values above 15 µmol/L, far too loose here. Requires a 10–12 hour fast; best paired with vitamin B12, folate and methylmalonic acid
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammation signal the supplement is proposed to lower Abbreviated hs-CRP on most laboratory reports. Conventional cut-off is 3.0 mg/L; testing is postponed for 2 weeks after any infection or unusually hard training session
Alanine aminotransferase Below 25 U/L in men, below 20 U/L in women Screens for liver strain from cumulative vitamin B3 load Abbreviated ALT. Conventional upper limits near 40–55 U/L miss early change; best paired with aspartate aminotransferase and gamma-glutamyl transferase
Glycated haemoglobin 4.8–5.4% NAD+ precursors as a class have been linked to higher plasma glucose Abbreviated HbA1c. Conventional laboratories call anything below 5.7% normal, which hides drift within that band. No fasting required, but unreliable with anaemia or recent blood loss; best paired with fasting insulin
Fasting glucose 75–90 mg/dL Same concern as above, with faster feedback between visits Conventional threshold of 100 mg/dL is far less sensitive. Requires a 10–12 hour fast; drawn with the morning panel
Systolic and diastolic blood pressure Below 120/80 mmHg The only cardiovascular signal produced in a controlled trial Seven days of seated home readings, morning and evening, beat any single clinic reading. The trial signal appeared only in those starting above 120 mmHg systolic
Prostate-specific antigen, men over 45 Below 1.0 ng/mL under age 50; below 2.0 ng/mL at age 60 The only practical screen bearing on the theoretical tumour-promotion concern Abbreviated PSA. The conventional cut-off of 4.0 ng/mL is far higher and misses the age-adjusted change this is meant to catch. Unreliable within 48 hours of cycling or ejaculation; a single value is uninformative without a trend across at least two draws

Qualitative markers worth recording alongside the laboratory panel:

  • Walking capacity — distance covered in six minutes, or time to onset of calf pain, retested every 3 months
  • Perceived daytime energy and afternoon fatigue, scored 1–10 each evening for a week before and after starting
  • Sleep quality and dream vividness, particularly in anyone dosing later than midday
  • Cognitive clarity and word-finding, judged against a fixed weekly task rather than general impression
  • Recovery from hard exercise sessions, measured as days to return to baseline soreness

Emerging Research

  • Phase 3 Parkinson’s disease readout (NOPARK): NCT03568968 randomised 410 people with early Parkinson’s disease to 1000 mg daily or placebo for 52 weeks, with total MDS-UPDRS as the primary endpoint. Completed June 2025, unpublished. The largest trial to date and the strongest available test of the neuroprotection case.

  • Blood pressure and arterial stiffness: NCT03821623, a phase 2 trial in 118 midlife and older adults with elevated systolic pressure, takes systolic blood pressure as its primary endpoint. It was designed specifically to test whether the exploratory 9 mmHg subgroup signal survives a properly powered trial.

  • Frailty and gait speed (NADage): NCT06208527, phase 2, 100 frail older adults, primary endpoint gait speed. Enrolment is restricted to adults over 75 scoring 3 or more on the Fried frailty phenotype. The first trial to take a functional ageing outcome, rather than a disease endpoint, as its primary target.

  • Confirmatory walking trial (NICE-PAD II): NCT07782671, phase 3, 250 people with peripheral artery disease, primary endpoint six-minute walk distance. Designed to establish whether the 2024 result replicates at a scale that supports inference.

  • Alzheimer’s disease (N-AD): NCT07741071, phase 2, 270 participants dosed for two years, primary endpoint the Clinical Dementia Rating sum of boxes. The longest planned exposure of any nicotinamide riboside trial.

  • Cardioprotection during chemotherapy: NCT05732051, phase 2, 60 breast cancer patients, testing whether nicotinamide riboside prevents chemotherapy-related decline in left ventricular function. Notable because it doses precisely the population in which the tumour-promotion concern is sharpest.

  • Whether the founding premise holds: Trętowicz et al., 2026 measured NAD+ across seven human cohorts and found whole-blood levels stable with age and unmoved by lifestyle interventions, while still responding to supplementation. If tissue data follow, the depletion rationale weakens regardless of trial outcomes.

  • How the compound actually works: Christen et al., 2026 found gut bacteria convert nicotinamide riboside to nicotinic acid, which then raises circulating NAD+ through a different pathway. Confirming this would reframe the compound as an indirect, expensive route to a cheap vitamin.

  • Replication of the cancer signal: Maric et al., 2023 reported increased tumour burden and brain metastasis in mice. Additional tumour models and pharmacovigilance in long-term human users are the obvious next steps; neither has been reported.

Conclusion

Nicotinamide riboside is a form of vitamin B3 that reliably raises the cell-energy molecule it is meant to raise. That much is settled across many trials and several doses. What follows from it is not. In people with narrowed leg arteries, six months of use lengthened walking distance in one trial; in early Parkinson’s disease, symptom scores improved slightly among those whose brain levels actually rose. Elsewhere the picture is inflammation markers moving in a favourable direction without any matching change in symptoms, events or function, and pooled trials in older adults finding no gain in strength, walking speed or muscle mass at all.

Side effects have been few and mild. In the trials that counted them properly, they were no more frequent than with placebo capsules. The concerns that remain are theoretical or preliminary: tumour growth in mice, a rise in one blood marker at very high doses, and a slowing of timed physical tests in people with memory impairment.

Two things weigh on the evidence base itself. Much of the human research was paid for by the companies selling the product, and the sellers of competing forms fund their own. And recent work has found the blood measure does not fall with age at all, unsettling the reason for taking it in the first place.

Top - Benefits - Risks - Protocol